The WHO declared the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo a public health emergency of international concern, reflecting the fast escalation and geographic spread into Uganda areas. The declaration highlighted the absence of licensed vaccines or antiviral treatments for this Ebola species and cited uncertainty about how much transmission is occurring beyond confirmed detection. A separate report said US authorities are tapping a small San Diego biotech to provide doses of an experimental antibody therapy as the epidemic worsens. The combined developments put experimental countermeasures into sharper focus as regulators and developers prepare for faster clinical ramp-ups. For the biotech sector, the situation is a reminder of how quickly translational pipelines can be pulled into emergency settings when outbreak dynamics accelerate.